Skip to main content

Both the

Dow Jones Industrial Average

and the Amex Pharmaceutical Index were on the rise as component


(MRK) - Get Free Report

lifted its profit forecast for full year by 20 cents.

The drugmaker's outlook took some of the sting out of word that an advisory panel to U.S. regulators voted to recommend Merck's pain drug Arcoxia be denied approval. Merck was surging by $3.68, or 7.9%, to $50.04.

Shares of

Amylin Pharmaceuticals

( AMLN), the maker of the diabetes drugs Symlin and Byetta, were also higher after Lazard Capital upgraded the company to hold from sell.

The firm said the impact of Merck's diabetes drug Januvia should fade over the next six to nine months. Amylin was recently up 81 cents, or 2.1%, to $39.76.

Other drugmakers were performing well.


( SGP) was adding 3%,

Bristol-Myers Squibb

(BMY) - Get Free Report

was up 2.4%, and


(PFE) - Get Free Report

was gaining nearly 1%.

Also among winners, biopharmaceutical company



said its DX-88 drug candidate tested well in a late-stage trial of patients suffering from the skin disease hereditary angioedema. Dyax was soaring $2.08, or 52%, to $6.08.

While the Amex Pharmaceutical Index was adding more than 2%, the Amex Biotechnology Index dipped 0.1% despite gains in


(AMGN) - Get Free Report


PDL BioPharma

(PDLI) - Get Free Report

of 3.1% and 2.4%, respectively. Fellow component

Vertex Pharmaceuticals

(VRTX) - Get Free Report

was down 6.4%.

Meanwhile, medical-device makers were having a tough go of it.

Varian Medical Systems

(VAR) - Get Free Report

dropped more than 8% after the company lowered its second-quarter revenue outlook following Thursday's closing bell. Varian was losing $3.96 to $44.98.

Other device makers were struggling.

Boston Scientific

(BSX) - Get Free Report

was losing 1.6% to $15.11,

Zimmer Holdings


was off 1.2% to $87.96, and


(MDT) - Get Free Report

slipped 0.4% to $50.78.